Linear covariate analysis of prognostically significant metabolites.... حسب Emir Matpan (21655811)

"…<p>Linear covariate analysis of prognostically significant metabolites. …"

Clinical diagnosis and abnormal signals of AEFIs(/10,000). حسب Chao Zhang (51048)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Confusion matrix for ClinicalBERT model. حسب Ahmed Akib Jawad Karim (20427740)

"…When compared to DistilBERT (66 million parameters) and ClinicalBERT (110 million parameters), LastBERT demonstrated comparable performance, with DistilBERT slightly outperforming it at 87%, and ClinicalBERT achieving 86% across the same metrics. …"

Data Sheet 1_Saccharomyces boulardii (CNCM I-745) improves intestinal damage in sepsis by remodeling intestinal flora structure.zip حسب Hui-Ying Liu (10193468)

"…</p>Results<p>Sepsis led to an increase in the expression of IL-6, TNF-α, and a decrease in the expression of occludin. After treatment with S. boulardii (CNCM I-745), the inflammatory damage with sepsis was reduced, and the expression level of occludin was significantly increased. …"

The top 20 candidate drugs demonstrating the most significant sensitivity differences between high- and low-GSRS subjects. حسب Yu Zhang (12946)

الموضوعات:

Clinical prognosis analysis of other DE-ERSRGs except PDHB. حسب Wan-Jing Zhen (20427813)

الموضوعات:

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. حسب Anneli Peolsson (7867601)

Data Sheet 1_Nicorandil reduces the antimicrobial effectiveness of polymyxin E against Klebsiella pneumoniae by decreasing reactive oxygen species accumulation.pdf حسب Rongqing Zhu (22261801)

Table 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…"

Table 2_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…"

Table 3_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…"

Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…"